CN103520717B - 丙氨酸作为疫苗佐剂的应用 - Google Patents
丙氨酸作为疫苗佐剂的应用 Download PDFInfo
- Publication number
- CN103520717B CN103520717B CN201310395462.3A CN201310395462A CN103520717B CN 103520717 B CN103520717 B CN 103520717B CN 201310395462 A CN201310395462 A CN 201310395462A CN 103520717 B CN103520717 B CN 103520717B
- Authority
- CN
- China
- Prior art keywords
- vaccine
- alanine
- adjuvant
- application
- inactivated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 title claims abstract description 22
- 235000004279 alanine Nutrition 0.000 title claims abstract description 22
- 239000012646 vaccine adjuvant Substances 0.000 title claims abstract description 13
- 229940124931 vaccine adjuvant Drugs 0.000 title claims abstract description 13
- 229960005486 vaccine Drugs 0.000 claims abstract description 31
- 241000607471 Edwardsiella tarda Species 0.000 claims description 4
- 230000009849 deactivation Effects 0.000 claims description 4
- 230000001900 immune effect Effects 0.000 abstract description 3
- 239000000568 immunological adjuvant Substances 0.000 abstract description 3
- 238000010171 animal model Methods 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 12
- 239000002671 adjuvant Substances 0.000 description 8
- 230000036039 immunity Effects 0.000 description 7
- 229940031551 inactivated vaccine Drugs 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 241000646933 Edwardsiella tarda EIB202 Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明涉及生物医药领域，具体公开了丙氨酸作为疫苗佐剂的应用。本发明通过在疫苗添加或不添加丙氨酸，发现试验动物在添加丙氨酸后较不添加丙氨酸的死亡率显著减少，说明丙氨酸可提高疫苗的免疫效果，可以作为疫苗的免疫佐剂。
Description
技术领域
本发明涉及生物医药领域，更具体地，涉及丙氨酸作为疫苗佐剂的应用。
背景技术
丙氨酸是构成蛋白质的基本单位，是组成人体蛋白质的21种氨基酸之一。它的分子式是C3H7O2N,具有预防肾结石、协助葡萄糖的代谢，有助缓和低血糖，改善身体能量。
疫苗佐剂是一类同抗原一起或预先注射进机体，能增强机体对该抗原的免疫应答或改变免疫应答类型的物质。目前最经典的疫苗佐剂是弗氏佐剂，但该佐剂主要用于动物实验，但动物多次注射后常会发生佐剂病。因此发现新的安全、有效、不会引起毒副作用的免疫佐剂具有很重要的应用价值。
发明内容
本发明所要解决的技术问题是，为了克服现有技术中疫苗佐剂种类的不足，提供丙氨酸作为疫苗佐剂的应用。
本发明所要解决的上述技术问题通过以下技术方案予以解决：
丙氨酸或其衍生物或其盐在制备疫苗佐剂方面的应用。
作为一种优选方案，所述的疫苗为灭活疫苗、减毒活疫苗或基因重组疫苗。
作为一种最优选方案，所述的疫苗为灭活迟钝爱德华菌疫苗。
丙氨酸在制备疫苗佐剂中的应用。
作为一种优选方案，所述的疫苗为灭活疫苗、减毒活疫苗或基因重组疫苗。
作为一种最优选方案，所述的疫苗为灭活迟钝爱德华菌疫苗。
丙氨酸作为疫苗佐剂在制备疫苗中的应用。
作为一种优选方案，所述的疫苗为灭活疫苗、减毒活疫苗或基因重组疫苗。作为一种最优选方案，所述的疫苗为灭活迟钝爱德华菌疫苗。
作为一种优选的方案，所述的疫苗为注射制剂，丙氨酸在所述注射制剂中的含量为10μmoL～1mol。
佐剂是非特异性免疫增强剂，当与抗原一起注射或预先注入机体时，可增强机体对抗原的免疫应答或改变免疫应答类型。可以作为佐剂的物质，例如弗氏佐剂，对所有疫苗均具有佐剂作用。故丙氨酸作为佐剂同样可用于任何种类疫苗佐剂。
本发明具有如下有益效果：（1）本发明提供了一种新型的疫苗免疫佐剂；（2）本发明所述的免疫佐剂安全、有效、不会引起毒副作用。
具体实施方式
以下结合具体实施例来进一步解释本发明，但实施例对本发明不做任何形式的限定。
实施例1迟钝爱德华菌EIB202菌株的培养和处理
挑取胰蛋白胨大豆肉汤培养基（TSB）平板上的迟钝爱德华菌EIB202单克隆于TSB试管中，30℃培养24h，按照1:100转接于100mL的TSB培养基中扩大培养。当OD600值达到1.0时离心收菌，用生理盐水洗涤两次后，用生理盐水悬浮菌体使OD600为1.0（细菌数约109个菌/毫升），用于实验小鼠的攻毒。
同时另取部分细菌，加入0.1%的甲醛，30℃孵育24小时使细菌灭活。然后用生理盐水洗涤3次后，用生理盐水悬浮使OD600为1.0（约109cfu/mL），再用生理盐水稀释10倍（约108cfu/mL），得灭活菌疫苗，用于实验小鼠的灭活菌免疫。
实施例2小鼠的免疫
90只4周龄昆明鼠（平均体重25g）随机分配成3组：对照组、灭活菌免疫组和灭活菌+丙氨酸免疫组。对照组每只小鼠腹腔注射100μL生理盐水；灭活菌免疫组每只小鼠腹腔注射上述制备好的灭活菌疫苗100μL（约107个细菌）；灭活菌+丙氨酸免疫组每只小鼠腹腔注射注射上述制备好的灭活菌疫苗100μL和内含丙氨酸120μmoL的混合物。连续免疫两次，间隔7天。最后1次免疫后7天，采用EIB202攻毒，剂量为3×108CFU/只，观察15天，统计小鼠的死亡情况。根据公式（相对免疫保护率=[1－(免疫对象的死亡率/未免疫对象的死亡率)]×100%）计算相，对免疫保护率。结果见表1。
表1小鼠的免疫效果
RPS为相对保护率，1是与与生理盐水对照组相比；2是与灭活疫苗免疫组相比；*P<0.05，**P<0.01。
此结果表明，灭活疫苗免疫动物后，与生理盐水对照组相比，免疫效果有显著性提高。而灭活疫苗同时添加丙氨酸后，比单纯使用灭活疫苗的保护率提高了38.9%。此结果说明，丙氨酸能够提高灭活菌疫苗的保护效率。
Claims (2)
1.一种疫苗，其特征在于，以丙氨酸为疫苗佐剂，所述的疫苗为灭活迟钝爱德华菌疫苗。
2.根据权利要求1所述的疫苗，其特征在于，所述疫苗为注射制剂，丙氨酸在所述注射制剂中的浓度为10μmoL~1mol。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310395462.3A CN103520717B (zh) | 2013-09-02 | 2013-09-02 | 丙氨酸作为疫苗佐剂的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310395462.3A CN103520717B (zh) | 2013-09-02 | 2013-09-02 | 丙氨酸作为疫苗佐剂的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103520717A CN103520717A (zh) | 2014-01-22 |
| CN103520717B true CN103520717B (zh) | 2015-11-18 |
Family
ID=49923302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310395462.3A Expired - Fee Related CN103520717B (zh) | 2013-09-02 | 2013-09-02 | 丙氨酸作为疫苗佐剂的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103520717B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109568575A (zh) * | 2018-12-02 | 2019-04-05 | 河南师范大学 | 一种增强嗜水气单胞菌OmpA疫苗接种效果的小分子代谢物佐剂及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1889976A (zh) * | 2003-10-30 | 2007-01-03 | 卢斯根有限责任公司 | 抗疱疹药物组合物、生产基于其的剂型的方法及其使用方法 |
| WO2008024075A1 (en) * | 2006-08-25 | 2008-02-28 | Agency For Science, Technology And Research | Modulators of candida hyphal morphogenesis and uses thereof |
| WO2008152654A1 (en) * | 2007-06-11 | 2008-12-18 | Panacea Biotec Limited | Anthrax fusion proteins, compositions and uses thereof |
| WO2008151633A2 (en) * | 2007-06-15 | 2008-12-18 | Skau Aps | Vectors for vaccines against lentivirus infections |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5955088A (en) * | 1992-02-03 | 1999-09-21 | Cedars-Sinai Medical Center | Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins |
-
2013
- 2013-09-02 CN CN201310395462.3A patent/CN103520717B/zh not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1889976A (zh) * | 2003-10-30 | 2007-01-03 | 卢斯根有限责任公司 | 抗疱疹药物组合物、生产基于其的剂型的方法及其使用方法 |
| WO2008024075A1 (en) * | 2006-08-25 | 2008-02-28 | Agency For Science, Technology And Research | Modulators of candida hyphal morphogenesis and uses thereof |
| WO2008152654A1 (en) * | 2007-06-11 | 2008-12-18 | Panacea Biotec Limited | Anthrax fusion proteins, compositions and uses thereof |
| WO2008151633A2 (en) * | 2007-06-15 | 2008-12-18 | Skau Aps | Vectors for vaccines against lentivirus infections |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103520717A (zh) | 2014-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103071151B (zh) | 猪支原体肺炎疫苗专用稀释剂及其制备方法 | |
| CN102847146B (zh) | 一种预防罗非鱼链球菌病的疫苗 | |
| CN102988981B (zh) | 一种增强爱德华氏菌疫苗免疫接种效果的佐剂及使用方法 | |
| CN104152368A (zh) | 罗非鱼源无乳链球菌弱毒株及应用 | |
| US20110236423A1 (en) | Immunogenic agents against burkholderia pseudomallei and/or burkholderia mallei, comprising lipopolysaccharide, capsular polysaccharide and/or proteins from burkholderia pseudomallei | |
| CN103520717B (zh) | 丙氨酸作为疫苗佐剂的应用 | |
| CN101157907A (zh) | 一种表达猪源支气管败血波氏杆菌fhaB和prn基因片段的重组猪霍乱沙门氏菌株、疫苗及应用 | |
| Denisov et al. | Immunopotentiation of live brucellosis vaccine by adjuvants | |
| JP2007326794A (ja) | 魚類ストレプトコッカス・ディスガラクティエを抗原とする不活化ワクチン | |
| Tahir et al. | Preparation and comparative evaluation of different adjuvanted toxoid vaccines against enterotoxaemia. | |
| CN106267176B (zh) | 鸡传染性鼻炎疫苗组合物及其制备方法和应用 | |
| CN101575586A (zh) | 一种支气管败血波氏杆菌基因缺失疫苗及应用 | |
| KR102077701B1 (ko) | 살모넬라 갈리나룸 사균체를 포함하는 가금 티푸스의 예방 또는 치료용 백신 조성물 | |
| JP6712760B2 (ja) | サルモネラワクチン | |
| CN106995489B (zh) | 一种猪链球菌截短蛋白Sao及应用 | |
| CN104971346A (zh) | 一种以壳寡糖为佐剂的鸭疫里默氏菌菌影疫苗 | |
| RU2227160C1 (ru) | Штамм бактерий leptospira interrogans "митронов" серогруппы canicola для приготовления вакцины | |
| JP7281208B2 (ja) | ＳｓｅＪタンパク質を用いたサルモネラワクチン | |
| KR102606461B1 (ko) | 살모넬라 엔터라이티디스 불활화 사균체를 포함하는 살모넬라증 예방 또는 치료용 백신 조성물 | |
| CN104248761A (zh) | 一种疫苗组合物及其制备方法和应用 | |
| NO310598B1 (no) | Middel og blanding for anvendelse som medikament, fremgangsmåte for fremstilling av middel, samt antistoffer | |
| Allan et al. | Innate immune cocktail partially protects broilers against cellulitis and septicemia | |
| RU2388488C1 (ru) | Вакцина против псевдомоноза нутрий | |
| Yanenko et al. | Prospect of Using B. Anthracis Exotoxin in the Design of Anti-Selective Emergency Preparations. | |
| RU2404802C1 (ru) | Вакцина против колибактериоза кроликов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151118 Termination date: 20210902 |